Active Ingredient(s): Isatuximab-irfc
FDA Approved: * March 2, 2020
Pharm Company: * SANOFI AVENTIS US
Category: Cancer

Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.[3][2] The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs).[2] Isatuxim... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Sarclisa 100 mg/5ml Intravenous Injection, Solution, Concentrate
NDC: 0024-0654
Sanof-aventis U.S. LLC
Sarclisa 500 mg/25ml Intravenous Injection, Solution, Concentrate
NDC: 0024-0656
Sanof-aventis U.S. LLC